Results fromthe first controlled study of hydroxychloroquine for treating COVID-19 showed no significant difference in outcomes between those who received the drug and those who received usual care. Hydroxychloroquine is one of several existing drugs that scientists are hoping will show improved symptoms and recovery in clinical trials for in patients with COVID-19.
However, the study’s small size and other weaknesses mean it does not offer a lot of helpful informa
tion in determining the possible utility of hydroxychloroquine, according to experts who reviewed the study. The study also tested only hydroxychloroquine alone, not with the antibiotic azithromycin.
“The combination therapy of azithromycin and hydroxychloroquine was thought to be better over the monotherapy of hydroxychloroquine to control the mixed infection of virus and bacteria,” explained Sunit K. Singh, PhD, a professor of molecular immunology & virology and head of the molecular biology unit at Banaras Hindu University’s Institute of Medical Sciences in
own by the brand name Plaquenil, is currently used to treat lupus and rheumatoid arthritis. It is slightly different from chloroquine phosphate, another drug, currently used to treat malaria, which is under investigation for treating COVID-19. Both drugs have been in use for decades but carry risks as well. “During any outbreaks of epidemic and pandemic levels, ther
e is hardly any time left for new drug development and clinical trials,” Dr. Singh said. Therefore clinicians will turn to trying existing drugs, known as “repurposing.”
Preprint (Chinese) of the study available at: Download Now